Novacyt announces 2014 Half Year Results and updates strong progress with integration of Lab21

Novacyt (ALTERNEXT: ALNOV), an international specialist in cancer and infectious disease diagnostics, today announces its half year results for the six months ended 30th June 2014 approved by the Board of Directors on 28th October 2014. Novacyt also provides an update on the progress of the recent integration of Lab21. Download press release

Visit Page

Revenues for the six months to June 30, 2014

Novacyt (Mmemo: ALNOV – FR0010397232) announces its sales for the six months ended June 30, 2014. Download press release

Visit Page

Novacyt and Lab21 Announce stock for stock Completion

Novacyt (NYSE-ALTERNEXT: ALNOV), a leading diagnostics manufacturer that develops and markets innovative solutions in liquid-based cytology for the detection of cancer, including cervical cancer and other non-gynaecological cancers, and Lab21, the Cambridge, UK-based global specialist in personalised medicine and clinical diagnostics, have completed their stock for stock transaction announced on 27 May, 2014. Download press

Visit Page